by Patel BD, Uppal R, Pulakundam N, Patel JP, Ramanathan V, Ameta R, Launay D, Braillard S. Bioanalysis 2019, 11(15):1419–1435. doi: 10.4155/bio-2019-0128
Summary: DNDI-VL-2098 is a nitroimidazo-oxazole class compound that shows activity in vitro and in vivo against Leishmania donovani and had potential as an agent against visceral leishmaniasis. However, based on toxicity data, it was not progressed for further development. Quantitative analysis during the development of DNDI-VL-2098 was challenging, due to compound instability in plasma at ambient temperature. In this study, the authors describe the development of a bioanalytical method to support pharmacokinetic evaluation of DNDI-VL-2098 in mouse, rat, dog, and hamster following oral administration. A robust and specific LC–MS/MS assay was developed and validated to quantify DNDI-VL-2098 in haemolyzed blood.